JP5948322B2 - ピロキシカム含有マトリックスパッチ、ならびにそれを用いる急性および慢性の疼痛および炎症の局所処置の方法 - Google Patents
ピロキシカム含有マトリックスパッチ、ならびにそれを用いる急性および慢性の疼痛および炎症の局所処置の方法 Download PDFInfo
- Publication number
- JP5948322B2 JP5948322B2 JP2013512249A JP2013512249A JP5948322B2 JP 5948322 B2 JP5948322 B2 JP 5948322B2 JP 2013512249 A JP2013512249 A JP 2013512249A JP 2013512249 A JP2013512249 A JP 2013512249A JP 5948322 B2 JP5948322 B2 JP 5948322B2
- Authority
- JP
- Japan
- Prior art keywords
- matrix
- adhesive
- piroxicam
- self
- matrix patch
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000011159 matrix material Substances 0.000 title claims description 662
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 title claims description 295
- 229960002702 piroxicam Drugs 0.000 title claims description 295
- 208000002193 Pain Diseases 0.000 title claims description 143
- 206010061218 Inflammation Diseases 0.000 title claims description 73
- 230000004054 inflammatory process Effects 0.000 title claims description 73
- 208000000094 Chronic Pain Diseases 0.000 title claims description 66
- 230000001154 acute effect Effects 0.000 title claims description 66
- 208000005298 acute pain Diseases 0.000 title claims description 66
- 238000000034 method Methods 0.000 title description 40
- 239000000853 adhesive Substances 0.000 claims description 387
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical group C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 118
- 229920006243 acrylic copolymer Polymers 0.000 claims description 99
- 239000004264 Petrolatum Substances 0.000 claims description 91
- 229940066842 petrolatum Drugs 0.000 claims description 91
- 235000019271 petrolatum Nutrition 0.000 claims description 91
- MEJYDZQQVZJMPP-ULAWRXDQSA-N (3s,3ar,6r,6ar)-3,6-dimethoxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan Chemical compound CO[C@H]1CO[C@@H]2[C@H](OC)CO[C@@H]21 MEJYDZQQVZJMPP-ULAWRXDQSA-N 0.000 claims description 87
- 229920002313 fluoropolymer Polymers 0.000 claims description 87
- 239000004811 fluoropolymer Substances 0.000 claims description 87
- 229920006267 polyester film Polymers 0.000 claims description 87
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 claims description 84
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 68
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 68
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 68
- 230000035515 penetration Effects 0.000 claims description 64
- 239000004820 Pressure-sensitive adhesive Substances 0.000 claims description 63
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 claims description 63
- 239000004745 nonwoven fabric Substances 0.000 claims description 61
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 59
- 239000002904 solvent Substances 0.000 claims description 48
- 150000001346 alkyl aryl ethers Chemical class 0.000 claims description 19
- 238000011200 topical administration Methods 0.000 claims description 10
- 208000025978 Athletic injury Diseases 0.000 claims description 8
- 230000006378 damage Effects 0.000 claims description 8
- 210000003127 knee Anatomy 0.000 claims description 8
- 208000036487 Arthropathies Diseases 0.000 claims description 7
- 206010006811 Bursitis Diseases 0.000 claims description 7
- 206010008690 Chondrocalcinosis pyrophosphate Diseases 0.000 claims description 7
- 208000034656 Contusions Diseases 0.000 claims description 7
- 208000005171 Dysmenorrhea Diseases 0.000 claims description 7
- 206010013935 Dysmenorrhoea Diseases 0.000 claims description 7
- 201000011275 Epicondylitis Diseases 0.000 claims description 7
- 201000005569 Gout Diseases 0.000 claims description 7
- 206010019233 Headaches Diseases 0.000 claims description 7
- 208000012659 Joint disease Diseases 0.000 claims description 7
- 208000036631 Metastatic pain Diseases 0.000 claims description 7
- 208000019695 Migraine disease Diseases 0.000 claims description 7
- 206010036376 Postherpetic Neuralgia Diseases 0.000 claims description 7
- 208000004550 Postoperative Pain Diseases 0.000 claims description 7
- 206010041738 Sports injury Diseases 0.000 claims description 7
- 208000010040 Sprains and Strains Diseases 0.000 claims description 7
- 208000000491 Tendinopathy Diseases 0.000 claims description 7
- 206010043255 Tendonitis Diseases 0.000 claims description 7
- 208000002240 Tennis Elbow Diseases 0.000 claims description 7
- 208000027418 Wounds and injury Diseases 0.000 claims description 7
- 208000003295 carpal tunnel syndrome Diseases 0.000 claims description 7
- 208000002849 chondrocalcinosis Diseases 0.000 claims description 7
- 230000009519 contusion Effects 0.000 claims description 7
- 231100000869 headache Toxicity 0.000 claims description 7
- 230000002757 inflammatory effect Effects 0.000 claims description 7
- 208000014674 injury Diseases 0.000 claims description 7
- 206010027599 migraine Diseases 0.000 claims description 7
- 201000008482 osteoarthritis Diseases 0.000 claims description 7
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 7
- 201000004415 tendinitis Diseases 0.000 claims description 7
- 208000008035 Back Pain Diseases 0.000 claims description 6
- 208000016247 Soft tissue disease Diseases 0.000 claims description 6
- 208000004296 neuralgia Diseases 0.000 claims description 6
- 208000021722 neuropathic pain Diseases 0.000 claims description 6
- 230000000699 topical effect Effects 0.000 claims description 5
- 238000001704 evaporation Methods 0.000 claims description 3
- 230000008020 evaporation Effects 0.000 claims description 3
- 239000010410 layer Substances 0.000 description 391
- 239000000203 mixture Substances 0.000 description 276
- 230000001070 adhesive effect Effects 0.000 description 140
- 238000005266 casting Methods 0.000 description 110
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 82
- 230000000774 hypoallergenic effect Effects 0.000 description 82
- 229920000573 polyethylene Polymers 0.000 description 82
- 241000124008 Mammalia Species 0.000 description 58
- 241000282412 Homo Species 0.000 description 57
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 55
- 238000011160 research Methods 0.000 description 55
- 229940079593 drug Drugs 0.000 description 35
- 239000003814 drug Substances 0.000 description 35
- 239000000463 material Substances 0.000 description 34
- 238000009736 wetting Methods 0.000 description 32
- 238000002156 mixing Methods 0.000 description 29
- 238000000935 solvent evaporation Methods 0.000 description 29
- 238000000807 solvent casting Methods 0.000 description 28
- 239000002313 adhesive film Substances 0.000 description 27
- 229940075557 diethylene glycol monoethyl ether Drugs 0.000 description 16
- KLDXJTOLSGUMSJ-JGWLITMVSA-N Isosorbide Chemical compound O[C@@H]1CO[C@@H]2[C@@H](O)CO[C@@H]21 KLDXJTOLSGUMSJ-JGWLITMVSA-N 0.000 description 12
- 229960002479 isosorbide Drugs 0.000 description 12
- 230000036407 pain Effects 0.000 description 11
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 8
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 8
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 7
- 239000004615 ingredient Substances 0.000 description 7
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- NIOYEYDJTAEDFH-UHFFFAOYSA-N 1-(2-hydroxyethoxy)-2-methylpropan-2-ol Chemical compound CC(C)(O)COCCO NIOYEYDJTAEDFH-UHFFFAOYSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 238000009835 boiling Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 229920006316 polyvinylpyrrolidine Polymers 0.000 description 3
- 238000007910 systemic administration Methods 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 206010040880 Skin irritation Diseases 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 229940035676 analgesics Drugs 0.000 description 2
- 239000000730 antalgic agent Substances 0.000 description 2
- 229940124599 anti-inflammatory drug Drugs 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 230000001627 detrimental effect Effects 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 230000036556 skin irritation Effects 0.000 description 2
- 231100000475 skin irritation Toxicity 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 2
- LZDKZFUFMNSQCJ-UHFFFAOYSA-N 1,2-diethoxyethane Chemical compound CCOCCOCC LZDKZFUFMNSQCJ-UHFFFAOYSA-N 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 206010024453 Ligament sprain Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000029549 Muscle injury Diseases 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000026137 Soft tissue injury Diseases 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000012790 adhesive layer Substances 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- -1 carrier Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000010579 first pass effect Methods 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000001087 glyceryl triacetate Substances 0.000 description 1
- 235000013773 glyceryl triacetate Nutrition 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 229920001600 hydrophobic polymer Polymers 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 208000013465 muscle pain Diseases 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 208000011906 peptic ulcer disease Diseases 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000000955 prescription drug Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- 239000013557 residual solvent Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229960002622 triacetin Drugs 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
- A61K9/7061—Polyacrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US39634710P | 2010-05-27 | 2010-05-27 | |
| US61/396,347 | 2010-05-27 | ||
| PCT/US2011/038189 WO2011150239A2 (en) | 2010-05-27 | 2011-05-26 | Piroxicam-containing matrix patches and methods for the topical treatment of acute and chronic pain and inflammation therewith |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015235438A Division JP2016033163A (ja) | 2010-05-27 | 2015-12-02 | ピロキシカム含有マトリックスパッチ、ならびにそれを用いる急性および慢性の疼痛および炎症の局所処置の方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013527197A JP2013527197A (ja) | 2013-06-27 |
| JP2013527197A5 JP2013527197A5 (https=) | 2014-07-10 |
| JP5948322B2 true JP5948322B2 (ja) | 2016-07-06 |
Family
ID=44352274
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013512249A Expired - Fee Related JP5948322B2 (ja) | 2010-05-27 | 2011-05-26 | ピロキシカム含有マトリックスパッチ、ならびにそれを用いる急性および慢性の疼痛および炎症の局所処置の方法 |
| JP2015235438A Pending JP2016033163A (ja) | 2010-05-27 | 2015-12-02 | ピロキシカム含有マトリックスパッチ、ならびにそれを用いる急性および慢性の疼痛および炎症の局所処置の方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015235438A Pending JP2016033163A (ja) | 2010-05-27 | 2015-12-02 | ピロキシカム含有マトリックスパッチ、ならびにそれを用いる急性および慢性の疼痛および炎症の局所処置の方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US8563031B2 (https=) |
| EP (1) | EP2575791B1 (https=) |
| JP (2) | JP5948322B2 (https=) |
| CN (1) | CN102970986B (https=) |
| AU (1) | AU2011258146A1 (https=) |
| CA (1) | CA2800716C (https=) |
| WO (1) | WO2011150239A2 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3054931B1 (en) * | 2013-10-07 | 2020-12-23 | Teikoku Pharma USA, Inc. | Transdermal delivery device for managing pain comprising dexmedetomidine transdermal compositions |
| TWI764951B (zh) | 2016-10-31 | 2022-05-21 | 美商帝國製藥美國股份有限公司 | 用於處理疼痛之右美托咪啶經皮遞送裝置 |
| CN107028921A (zh) * | 2017-05-16 | 2017-08-11 | 蔡志浩 | 一种吡罗昔康巴布贴剂 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5989586A (en) | 1992-10-05 | 1999-11-23 | Cygnus, Inc. | Two-phase matrix for sustained release drug delivery device |
| ES2160623T3 (es) * | 1992-12-31 | 2001-11-16 | Sunkyong Ind Ltd | Composiciones farmaceuticas mejoradas para la penetracion en la piel de piroxicam. |
| AU6635294A (en) | 1993-04-22 | 1994-11-08 | Minnesota Mining And Manufacturing Company | Transdermal antiinflammatory composition |
| DE4405898A1 (de) * | 1994-02-18 | 1995-08-24 | Schering Ag | Transdermale therapeutische Systeme enthaltend Sexualsteroide |
| JP3305101B2 (ja) * | 1994-03-29 | 2002-07-22 | 積水化学工業株式会社 | 経皮吸収製剤 |
| JPH08295624A (ja) * | 1995-04-26 | 1996-11-12 | Read Chem Kk | プラスター基剤、その製造方法、該基剤を使用した外用貼 付剤 |
| KR100294084B1 (ko) * | 1998-06-02 | 2001-09-22 | 성재갑 | 비-스테로이드성소염진통제의경피흡수투여용조성물및이를포함하는경피흡수투여용제형 |
| EP1233763B1 (de) * | 1999-11-29 | 2003-07-30 | LTS Lohmann Therapie-Systeme AG | Transdermale therapeutische systeme mit verbesserter stabilität und ein verfahren zu ihrer herstellung |
| US6645520B2 (en) * | 1999-12-16 | 2003-11-11 | Dermatrends, Inc. | Transdermal administration of nonsteroidal anti-inflammatory drugs using hydroxide-releasing agents as permeation enhancers |
| BR0207955A (pt) | 2001-03-07 | 2004-02-25 | Hisamitsu Pharmaceutical Co | Agente de emplastro |
| US20050020658A1 (en) * | 2002-11-21 | 2005-01-27 | Katsuyuki Inoo | Selective cyclooxygenase-2 inhibitor patch |
| US20040127531A1 (en) * | 2002-11-21 | 2004-07-01 | Lu Guang Wei | Adhesive coated sheet for dermal delivery of a selective cyclooxygenase-2 inhibitor |
| KR100552650B1 (ko) | 2003-11-17 | 2006-02-20 | 아이큐어 주식회사 | 피록시캄 함유 소염진통용 플라스터 |
| JP2007511544A (ja) * | 2003-11-19 | 2007-05-10 | アクルックス・ディ・ディ・エス・プロプライエタリー・リミテッド | アミロイド症の予防若しくは治療のための組成物および方法 |
| US20070196457A1 (en) * | 2004-06-07 | 2007-08-23 | Jie Zhang | Two or more volatile solvent-containing compositions and methods for dermal delivery of drugs |
| DE102004062614B4 (de) * | 2004-12-24 | 2011-12-29 | Lts Lohmann Therapie-Systeme Ag | Transdermales therapeutisches System mit aktivierbarer Übersättigung und kontrollierter Permeationförderung sowie Verfahren zu dessen Herstellung |
| US20080226698A1 (en) * | 2007-03-16 | 2008-09-18 | Mylan Technologies, Inc. | Amorphous drug transdermal systems, manufacturing methods, and stabilization |
| EP2676680A1 (de) * | 2007-09-13 | 2013-12-25 | Basf Se | Verwendung von Hydrophobin-Polipeptiden als Penetrationsverstärker |
-
2011
- 2011-05-25 US US13/115,898 patent/US8563031B2/en not_active Expired - Fee Related
- 2011-05-26 EP EP11727855.6A patent/EP2575791B1/en not_active Not-in-force
- 2011-05-26 JP JP2013512249A patent/JP5948322B2/ja not_active Expired - Fee Related
- 2011-05-26 WO PCT/US2011/038189 patent/WO2011150239A2/en not_active Ceased
- 2011-05-26 CA CA2800716A patent/CA2800716C/en not_active Expired - Fee Related
- 2011-05-26 AU AU2011258146A patent/AU2011258146A1/en not_active Abandoned
- 2011-05-26 CN CN201180031485.5A patent/CN102970986B/zh active Active
-
2013
- 2013-10-21 US US14/059,375 patent/US20140046274A1/en not_active Abandoned
-
2015
- 2015-12-02 JP JP2015235438A patent/JP2016033163A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2011150239A2 (en) | 2011-12-01 |
| US8563031B2 (en) | 2013-10-22 |
| US20110293721A1 (en) | 2011-12-01 |
| CA2800716A1 (en) | 2011-12-01 |
| AU2011258146A1 (en) | 2012-12-20 |
| US20140046274A1 (en) | 2014-02-13 |
| EP2575791B1 (en) | 2018-08-08 |
| CN102970986A (zh) | 2013-03-13 |
| EP2575791A2 (en) | 2013-04-10 |
| JP2016033163A (ja) | 2016-03-10 |
| JP2013527197A (ja) | 2013-06-27 |
| CA2800716C (en) | 2019-11-05 |
| WO2011150239A3 (en) | 2012-06-07 |
| CN102970986B (zh) | 2015-06-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP3908795B2 (ja) | ケトチフェン含有経皮投与製剤 | |
| JP5542665B2 (ja) | マトリックス型経皮投与剤およびその製造方法 | |
| JP3836566B2 (ja) | フェンタニル含有経皮投与テープ製剤 | |
| US8852628B1 (en) | Transdermal drug delivery system for diclofenac | |
| TW201431554A (zh) | 左炔諾孕酮（ｌｅｖｏｎｏｒｇｅｓｔｒｅｌ）及乙烯雌二醇之經皮藥物遞送系統 | |
| JP2006509761A (ja) | 選択的シクロオキシゲナーゼ−２阻害剤の皮膚デリバリーのための粘着剤塗被シート | |
| JP5948322B2 (ja) | ピロキシカム含有マトリックスパッチ、ならびにそれを用いる急性および慢性の疼痛および炎症の局所処置の方法 | |
| JP5535640B2 (ja) | フェンタニル含有経皮吸収製剤 | |
| JP7354242B2 (ja) | イブプロフェンまたはその構造類似体を含む多層経皮薬物送達システム | |
| WO2021098791A1 (zh) | 一种含有美金刚的透皮贴剂 | |
| JP2002516879A (ja) | 非ステロイド性消炎鎮痛剤の経皮投与用組成物 | |
| WO2004024155A1 (ja) | 貼付剤 | |
| JPH04178323A (ja) | 経皮投与製剤 | |
| CN1827094A (zh) | 一种凝胶型右旋酮洛芬贴剂及其制备方法 | |
| JP4764337B2 (ja) | 消炎鎮痛貼付剤 | |
| JP2010006761A (ja) | フェンタニルまたはその塩を含有する経皮吸収型貼付剤およびその製造方法 | |
| US20200375915A1 (en) | Matrix adhesive patch and process for the preparation thereof | |
| CN117899056B (zh) | 含利多卡因的透皮贴剂及其制备方法和用途 | |
| US20260014095A1 (en) | Patch containing colchicine and preparation method and use thereof | |
| TW202440102A (zh) | 含多奈哌齊之經皮吸收製劑 | |
| JP2018524348A (ja) | レボノルゲストレルおよびエチニルエストラジオールのための経皮的薬物送達システム | |
| CN116898831A (zh) | 一种含有s-氟比洛芬的外用剂组合物 | |
| JPH08165240A (ja) | ケトチフェン含有経皮投与製剤 | |
| JPS6351333A (ja) | デプロドンプロピオネ−ト含有外用貼付剤 | |
| HK1117029A (en) | Transdermal method and patch for nausea |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140523 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20140523 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20150415 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20150612 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150710 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20150902 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20151202 |
|
| RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20151221 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20151215 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160119 Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20160119 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20160209 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20160329 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20160524 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20160606 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 5948322 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |